文献简介

出版社:Dermatol Clin

作  者:Thomas S. Bander, MD , Kishwer S. Nehal, MD , Erica H. Lee, MD

编  号:

关键字:鳞状细胞癌;管理;分期

年  份:2019   点击量:64

文献摘要 全文翻译

INTRODUCTION

简介

 

Cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in the United States. Together with basal cell carcinoma (BCC), these cancers of epidermal keratinocyte lineage are often referred to as non-melanoma skin cancer, or more specifically, keratinocyte carcinoma to differentiate their origins from melanoma and other skin cancers, such as Merkel cell carcinoma, adnexal carcinoma, and dermatofibrosarcoma protuberans. Although cSCC and BCC have many similarities, a subset of cSCC is biologically distinct and requires a different approach because of its higher risk of local recurrence, metastasis, and death. This article focuses on the recent literature regarding identification of this high-risk subset, efforts to improve the prognostic ability of staging systems, and updates in management. Much of these data and expert opinion are incorporated in recent cSCC guidelines.


皮肤鳞状细胞癌(cSCC)是美国最常见的癌症之一。与基底细胞癌(BCC)一样,这些表皮角质细胞癌通常被称为非黑色素瘤性皮肤癌,或者更具体地说,角化细胞癌,以区别于黑色素瘤和其他皮肤癌,如Merkel细胞癌、附件癌和隆突性皮肤纤维肉瘤。虽然cSCC和BCC有许多相似之处,但cSCC一亚型生物学上不同,且由于其局部复发性,转移和死亡风险较高,因此治疗方法不同。本文重点关注识别此高风险亚型,改善分期系统预后能力,提高管理的最新文献。这些数据和专家意见大部分被纳入了最近的cSCC指南。